Medical cannabis treatmente for migraine: na integrative review
DOI:
https://doi.org/10.55892/jrg.v9i20.3224Keywords:
Migraine, Medical cannabis, Cannabinoids, Cannabis, Endocannabinoid systemAbstract
Migraine is one of the most common pain complaints in medical practice and one of the most disabling diseases worldwide. Currently, it is widely treated with NSAIDs and simple analgesics. Cannabis has been used by humanity for thousands of years in the treatment of painful conditions such as migraine, and its active substances, the phytocannabinoids, interact with the endocannabinoid system. This study aims to evaluate the potential benefits of medical cannabis use in the clinical management of patients affected by migraines. It consists of an integrative literature review conducted through searches in the PubMed and Lilacs/VHL databases, including 9 scientific articles published within the last 10 years that address the use of medical cannabis in migraine treatment. Based on the results of this review, it was observed that the use of medical cannabis helps control migraine symptoms. Among the primary benefits are its potential to reduce the frequency and intensity of painful migraine attacks. However, despite the promising results, there is still a scarcity of studies on the use of medical cannabis, requiring more specific studies with greater scientific rigor to validate its efficacy and safety in treating migraines.
Downloads
References
AKERMAN, S.; KAUBE, H.; GOADSBY, P. J. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. British Journal of Pharmacology, v. 142, n. 8, p. 1354–1360, ago. 2004. Disponível em: https://doi.org/10.1038/sj.bjp.0705896. Acesso em: 23 abr. 2026.
ASHINA, Sait; TERWINDT, Gisela M.; STEINER, Timothy J.; LEE, Mi Ji; PORRECA, Frank; TASSORELLI, Cristina; SCHWEDT, Todd J.; JENSEN, Rigmor H.; DIENER, Hans-Christoph; LIPTON, Richard B. Medication overuse headache. Nature Reviews Disease Primers, v. 9, n. 1, p. 5, 2023. Disponível em: https://doi.org/10.1038/s41572-022-00415-0. Acesso em: 12 abr. 2026.
AVIRAM, Joshua; VYSOTSKI, Yelena; BERMAN, Paula; LEWITUS, Gil M.; EISENBERG, Elon; MEIRI, David. Migraine frequency decrease following prolonged medical cannabis treatment: a cross-sectional study. Brain Sciences, Basel, v. 10, n. 6, art. 360, 2020. Disponível em: https://doi.org/10.3390/brainsci10060360. Acesso em: 30 mar. 2026.
BARALDI, Carlo; LO CASTRO, Flavia; NEGRO, Andrea; FERRARI, Anna; CAINAZZO, Maria Michela; PANI, Luca; GUERZONI, Simona. Oral cannabinoid preparations for the treatment of chronic migraine: a retrospective study. Pain Medicine, v. 23, n. 2, p. 396–402, 2022. Disponível em: https://doi.org/10.1093/pm/pnab245. Acesso em: 23 abr. 2026.
CLAPPER, Jason R.; MORENO-SANZ, Gonzalo; RUSSO, Rosario; GUIJARRO, Antonio; VACONDIO, Federico; DURANTI, Alessia; TONTINI, Andrea; SANCHINI, Silvia; SCIOLINO, Natasha R.; SPRADLEY, Jason M.; HOHMANN, Andrea G.; CALIGNANO, Anna; MOR, Marco; TARZIA, Giorgio; PIOMELLI, Daniele.
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience, v. 13, n. 10, p. 1265–1270, out. 2010. Disponível em: https://doi.org/10.1038/nn.2632. Acesso em: 23 abr. 2026.
CUTTLER, Carrie; SPRADLIN, Alexander; CLEVELAND, Michael J.; CRAFT, Rebecca M. Short- and long-term effects of cannabis on headache and migraine. The Journal of Pain, v. 21, n. 5-6, p. 722–730, maio/jun. 2020. Disponível em: https://doi.org/10.1016/j.jpain.2019.11.001. Acesso em: 17 abr. 2026.
DEEN, Marie; CHRISTENSEN, Casper Emil; HOUGAARD, Anders; HANSEN, Hanne Demant; KNUDSEN, Gitte Moos; ASHINA, Messoud. Serotonergic mechanisms in the migraine brain: a systematic review. Cephalalgia, v. 37, n. 3, p. 251–264, mar. 2017. Disponível em: https://doi.org/10.1177/0333102416640501. Acesso em: 12 abr. 2026.
DU TOIT, Brian M. Cannabis in Africa: a survey of its distribution in Africa, and a study of cannabis use and users in multi-ethnic South Africa. Rotterdam: A. A. Balkema, 1980. 512 p.
ELSOHLY, Mahmoud A.; RADWAN, Mohamed M.; GUL, Waseem; CHANDRA, Suman; GALAL, Ahmed. Phytochemistry of Cannabis sativa L. In: KINGHORN, A. Douglas; FALK, Heinz; GIBBONS, Simon; KOBAYASHI, Jun’ichi (ed.). Progress in the Chemistry of Organic Natural Products. Cham: Springer, 2017. v. 103, p. 1–36. Disponível em: https://doi.org/10.1007/978-3-319-45541-9_1. Acesso em: 23 abr. 2026.
FINN, David P.; HAROUTOUNIAN, Simon; HOHMANN, Andrea G.; KRANE, Elliot; SOLIMAN, Nadia; RICE, Andrew S. C. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain, v. 162, supl. 1, p. S5–S25, jul. 2021. Disponível em: https://doi.org/10.1097/j.pain.0000000000002268. Acesso em: 23 abr. 2026.
GOADSBY, P. J.; EDVINSSON, L.; EKMAN, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology, v. 23, n. 2, p. 193–196, fev. 1988. DOI: https://doi.org/10.1002/ana.410230214
GROSSO, Adriana F. Cannabis: de planta condenada pelo preconceito a uma das grandes opções terapêuticas do século. Journal of Human Growth and Development, São Paulo, v. 30, n. 1, p. 94–97, abr. 2020. Disponível em: https://doi.org/10.7322/jhgd.v30.9977. Acesso em: 12 abr. 2026.
HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, London, v. 38, n. 1, p. 1-211, jan. 2018. DOI: https://doi.org/10.1177/0333102417738202. Disponível em: https://ichd-3.org/. Acesso em: 12 abr. 2026.
IYENGAR, Smriti; JOHNSON, Kirk W.; OSSIPOV, Michael H.; AURORA, Sheena K. CGRP and the trigeminal system in migraine. Headache, v. 59, n. 5, p. 659–681, maio 2019. Disponível em: https://doi.org/10.1111/head.13529. Acesso em: 12 abr. 2026.
KALANT, Harold. Medicinal use of cannabis: history and current status. Pain Research and Management, v. 6, n. 2, p. 80–91, 2001. Disponível em: https://doi.org/10.1155/2001/469629. Acesso em: 22 abr. 2026.
LU, Hui-Chen; MACKIE, Ken. An introduction to the endogenous cannabinoid system. Biological Psychiatry, v. 79, n. 7, p. 516–525, abr. 2016. Disponível em: https://doi.org/10.1016/j.biopsych.2015.07.028. Acesso em: 23 abr. 2026.
LU, Hui-Chen; MACKIE, Ken. Review of the endocannabinoid system. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, v. 6, n. 6, p. 607–615, jun. 2021. Disponível em: https://doi.org/10.1016/j.bpsc.2020.07.016. Acesso em: 23 abr. 2026.
MECHTLER, Laszlo; BARGNES, Victoria; HART, Paul; MCVIGE, Jennifer; SAIKALI, Nabil. Medical cannabis for chronic migraine: a retrospective review. Neurology, v. 92, n. 15, Supplement, 2019. Disponível em: https://doi.org/10.1212/WNL.92.15_supplement.P3.10-015. Acesso em: 30 mar. 2026.
OKUSANYA, Babasola O.; LOTT, Breanne E.; EHIRI, John; MCCLELLAND, Jean; ROSALES, Cecilia. Medical cannabis for the treatment of migraine in adults: a review of the evidence. Frontiers in Neurology, v. 13, art. 871187, 2022. Disponível em: https://doi.org/10.3389/fneur.2022.871187. Acesso em: 30 mar. 2026
PELLESI, Lanfranco; DO, Thien Phu; HOUGAARD, Anders. Pharmacological management of migraine: current strategies and future directions. Expert Opinion on Pharmacotherapy, v. 25, n. 6, p. 673–683, 2024. Disponível em: https://doi.org/10.1080/14656566.2024.2349791. Acesso em: 12 abr. 2026.
POUDEL, Sujan; QUINONEZ, Jonathan; CHOUDHARI, Jinal; AU, Zachary T.; PAESANI, Sylvia; THIESS, Armond K.; RUXMOHAN, Samir; HOSAMEDDIN, Mobashir; FERRER, Gerardo F.; MICHEL, Jack. Medical cannabis, headaches, and migraines: a review of the current literature. Cureus, v. 13, n. 8, e17407, 2021. Disponível em: https://doi.org/10.7759/cureus.17407. Acesso em: 30 mar. 2026.
REN, Guangpeng; ZHANG, Xu; LI, Ying; RIDOUT, Kate; SERRANO-SERRANO, Martha L.; YANG, Yongzhi; LIU, Ai; RAVIKANTH, Gudasalamani; NAWAZ, Muhammad Ali; MUMTAZ, Abdul Samad; SALAMIN, Nicolas; FUMAGALLI, Luca.
Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa. Science Advances, v. 7, n. 29, 2021. Disponível em: https://doi.org/10.1126/sciadv.abg2286. Acesso em: 23 abr. 2026
RHYNE, Danielle N.; ANDERSON, Sarah L.; GEDDE, Margaret; BORGELT, Laura M. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy, v. 36, n. 5, p. 505–510, maio 2016. Disponível em: https://doi.org/10.1002/phar.1673. Acesso em: 23 abr. 2026.
RODRÍGUEZ DE FONSECA, Fernando; DEL ARCO, Ignacio; BERMUDEZ-SILVA, Francisco Javier; BILBAO, Ainhoa; CIPPITELLI, Andrea; NAVARRO, Miguel. The endocannabinoid system: physiology and pharmacology. Alcohol and Alcoholism, v. 40, n. 1, p. 2–14, jan./fev. 2005. Disponível em: https://doi.org/10.1093/alcalc/agh110. Acesso em: 23 abr. 2026.
ROPPER, Allan H.; SAMUELS, Martin A.; KLEIN, Joshua P.; PRASAD, Sashank. Adams and Victor's Principles of Neurology. 12. ed. New York: McGraw-Hill,
RUSSO, Ethan B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, v. 1, n. 1, p. 154–165, 2016. Disponível em: https://doi.org/10.1089/can.2016.0009. Acesso em: 23 abr. 2026.
RUSSO, Ethan B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letters, v. 25, n. 1-2, p. 31–39, 2004. Disponível em: https://pubmed.ncbi.nlm.nih.gov/15159679/. Acesso em: 23 abr. 2026.
SARCHIELLI, Paola; PINI, Luigi Alberto; COPPOLA, Francesca; ROSSI, Cristiana; BALDI, Antonio; MANCINI, Maria Luisa; CALABRESI, Paolo. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology, v. 32, n. 6, p. 1384–1390, jun. 2007. Disponível em: https://doi.org/10.1038/sj.npp.1301246 . Acesso em: 23 abr. 2026.
SCHUSTER, Nathaniel M.; WALLACE, Mark S.; MARCOTTE, Thomas D.; BUSE, Dawn C.; LEE, Euyhyun; LIU, Lin; SEXTON, Michelle. Vaporized cannabis versus placebo for acute migraine: a randomized, double-blind, placebo-controlled crossover trial. Headache, v. 66, n. 2, p. 365–376, fev. 2026. Disponível em: https://doi.org/10.1111/head.70025. Acesso em: 23 abr. 2026.
SHERPA, Mingma L.; SHRESTHA, Nilasma; OJINNA, Blessing T.; RAVI, Niriksha; KUMAR, Vivig Shantha; CHODAY, Silpa; PARISAPOGU, Anusha; TRAN, Hadrian Hoang-Vu; KC, Anil; ELSHAIKH, Abeer O. Efficacy and safety of medical marijuana in migraine headache: a systematic review. Cureus, v. 14, n. 12, 2022. Disponível em: https://doi.org/10.7759/cureus.32622. Acesso em: 23 abr. 2026.
SOCIEDADE BRASILEIRA DE CEFALEIA. Consenso Brasileiro para o Tratamento da Enxaqueca. São Paulo: SBCe, 2022. Disponível em: https://www.thiemeconnect.com/products/ejournals/pdf/10.1055/s-0042-1756441.pdf. Acesso em: 12 abr. 2026.
STARKEY, Brian; PEARLSON, Godfrey D.; BOND, David S.; GLASER, Carly; BHARGAVA, Anu; GROSBERG, Brian M.; VERHAAK, Anouk. Characterizing cannabis use and perceived benefit in a tertiary headache center patient sample. Neurology Clinical Practice, v. 14, n. 2, p. e200285, abr. 2024. Disponível em: https://doi.org/10.1212/CPJ.0000000000200285. Acesso em: 17 abr. 2026
STEINER, Timothy J.; STOVNER, Lars Jacob. Global epidemiology of migraine and its implications for public health and health policy. Nature Reviews Neurology, v. 19, n. 2, p. 109–125, 2023. Disponível em: https://doi.org/10.1038/s41582-022-00763-1. Acesso em: 23 abr. 2026.
WALKER, J. M.; HUANG, S. M.; STRANGMAN, N. M.; TSOU, K.; SAÑUDO-PEÑA, M. C. Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America, v. 96, n. 21, p. 12198–12203, out. 1999. Disponível em: https://doi.org/10.1073/pnas.96.21.12198. Acesso em: 23 abr. 2026.
